STERIS plc (STE) · Nov 4, 2026 · New debt
Acquisition financing — $1.6B revolver plus up to $500M delayed-draw term loan
STERIS’s acquisition financing adds a larger revolver and a delayed-draw loan for Xodus, improving funding flexibility but increasing eventual leverage.
STERIS is expanding its healthcare consumables platform through the planned acquisition of Xodus Medical, a specialty surgical-products company focused on operating-room safety. The acquisition was already announced at $2.1 billion, with closing expected by December 31, 2026, and management said it would be financed primarily with debt.
The filing converts the acquisition’s funding plan into committed financing. STERIS replaces its $1.1 billion 2024 revolver with a $1.6 billion facility and adds a separate delayed-draw term loan of up to $500 million, giving it substantial capacity to fund Xodus without borrowing immediately. The new revolver can also be expanded by another $800 million, although that is only an option subject to lender approval.
| Facility / metric (Item 1.01) | November 4, 2026 | Prior facility / limit |
|---|---|---|
| Revolving credit facility | $1.6B | $1.1B |
| Delayed-draw term loan | $500M | — |
| Additional revolver capacity | $800M | — |
| Alternative-currency sublimit | $625M | — |
The immediate balance-sheet impact is limited, but the eventual leverage impact is real. No borrowing was made when the new revolver closed, and the $500 million term loan cannot be used unless the Xodus acquisition closes. That means this filing is primarily a financing-readiness event today, not evidence that STERIS has already added the full debt burden. 〔0〕
Relative to the standing story, this is supportive but not a fresh strategic surprise. STERIS had already disclosed that Xodus would be financed primarily with debt, so the direction was known; the new information is the size and structure of the committed facilities. The financing preserves flexibility to complete the deal, but it also makes the acquisition’s future leverage more tangible. The 2024 revolver was $1.1 billion, so the replacement represents a $500 million increase in committed revolving capacity before considering the separate term loan.
Bottom line: This filing advances the Xodus acquisition by securing the funding framework, but it does not yet change STERIS’s operating business or show debt actually drawn. It is a modestly constructive execution step offset by clearer future leverage exposure.
Xodus closing, expected by December 31, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!